News
INNMF
0.100
NaN%
--
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
Barchart · 22h ago
Amplia bolsters narmafotinib case with comprehensive pancreatic cancer data
TipRanks · 1d ago
Amplia advances FAK inhibitor program with new trials, patent gains and board refresh
TipRanks · 3d ago
Amplia Therapeutics Issues New Employee Incentive Options
TipRanks · 07/15 08:38
Amplia Announces Publication of New FAK Inhibitor Patent Application
Barchart · 07/09 07:45
Amplia Therapeutics appoints Brett Carter as non-executive director
PUBT · 07/07 12:45
AMPLIA ANNOUNCES APPOINTMENT OF BRETT CARTER TO BOARD
Reuters · 07/07 12:45
Amplia Therapeutics names Jane Bell chair as Warwick Tong steps down
PUBT · 07/06 12:45
Amplia Announces Changes to Board’s Leadership Roles
Barchart · 07/06 07:45
Amplia Therapeutics appoints Brett Carter as director amid progress in pancreatic cancer trials
TipRanks · 07/06 07:13
Amplia Therapeutics appoints Brett Carter as non-executive director to board
PUBT · 07/05 23:18
Amplia strengthens board with industry deal-maker Brett Carter
TipRanks · 07/05 23:08
Amplia Therapeutics Sets August AGM Amid Progress in FAK Cancer Trials
TipRanks · 06/30 23:39
Amplia Therapeutics reshapes board leadership as clinical momentum builds
TipRanks · 06/29 22:43
Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
Barchart · 06/22 07:45
Amplia lodges updated ASX corporate governance statement for 2026
TipRanks · 05/29 05:57
Amplia Therapeutics details ASX-aligned corporate governance framework
TipRanks · 05/29 03:58
Amplia Highlights Cancer and Fibrosis Focus in 2025-26 Report
TipRanks · 05/29 03:48
Amplia launches Phase 2b pancreatic cancer trial of narmafotinib with daily dosing
PUBT · 05/19 12:45
Amplia Therapeutics launches Phase 2b narmafotinib trial in advanced pancreatic cancer
PUBT · 05/18 22:58
More
Webull provides a variety of real-time INNMF stock news. You can receive the latest news about Amplia Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About INNMF
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.